Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 14 de 14
Filter
1.
JAMA Netw Open ; 6(4): e2310687, 2023 04 03.
Article in English | MEDLINE | ID: mdl-37115546

ABSTRACT

Importance: Vaccine responses are decreased in solid organ transplant (SOT) recipients, and given the complexity of implementation, vaccination programs may be suboptimal. The actual burden of vaccine-preventable infections (VPIs) among SOT recipients remains unclear. Objectives: To assess the incidence rate of VPIs among SOT recipients and to evaluate whether SOT recipients are at increased risk for specific VPIs compared with the general population. Design, Setting, and Participants: This nationwide cohort study used data from the Swiss Transplant Cohort Study on VPIs in individuals who underwent SOT from May 2008 to June 2019 (follow-up until December 2019) and data from the Swiss Federal Office of Public Health on notifiable VPIs in the general population in the same period. Data were analyzed from January 2021 to June 2022. Exposures: Solid organ transplant. Main Outcomes and Measures: The main outcomes were the incidence rate of the following VPIs in SOT recipients: hepatitis A and B, diphtheria, Haemophilus influenzae infection, influenza, measles, mumps, pertussis, pneumococcal disease, poliomyelitis, meningococcal disease, rubella, tetanus, tick-borne encephalitis, and varicella zoster virus infection. Age-adjusted standardized incidence ratios were used to assess whether VPIs occurred more frequently in SOT recipients compared with the general population. For SOT recipients, factors associated with occurrence of VPIs were explored and the associated morbidity and mortality assessed. Results: Of 4967 SOT recipients enrolled (median age, 54 years [IQR, 42-62 years]; 3191 [64.2%] male), 593 (11.9%) experienced at least 1 VPI. The overall VPI incidence rate was higher in the population that underwent SOT (30.57 per 1000 person-years [PY]; 95% CI, 28.24-33.10 per 1000 PY) compared with the general population (0.71 per 1000 PY). The standardized age-adjusted incidence ratio for notifiable VPIs in SOT recipients was higher compared with the general population (27.84; 95% CI, 25.00-31.00). In SOT recipients, influenza and varicella zoster virus infection accounted for most VPI episodes (16.55 per 1000 PY [95% CI, 14.85-18.46 per 1000 PY] and 12.83 per 1000 PY [95% CI, 11.40-14.44 per 1000 PY], respectively). A total of 198 of 575 VPI episodes in the population that underwent SOT (34.4%) led to hospital admission, and the occurrence of a VPI was associated with an increased risk for death and/or graft loss (hazard ratio, 2.44; 95% CI, 1.50-3.99; P = .002). In multivariable analysis, age 65 years or older at the time of transplant (incidence rate ratio [IRR], 1.29; 95% CI, 1.02-1.62) and receipt of a lung (IRR, 1.77; 95% CI, 1.38-2.26) or a heart (IRR, 1.40; 95% CI, 1.05-1.88) transplant were associated with an increased risk of VPI occurrence. Conclusions and Relevance: In this study, 11.9% of SOT recipients experienced VPIs, and the incidence rate was higher than in the general population. There was significant morbidity and mortality associated with these infections in the population that underwent SOT, which highlights the need for optimizing immunization strategies.


Subject(s)
Communicable Diseases , Influenza, Human , Organ Transplantation , Vaccines , Varicella Zoster Virus Infection , Aged , Female , Humans , Male , Middle Aged , Cohort Studies , Communicable Diseases/epidemiology , Switzerland/epidemiology , Varicella Zoster Virus Infection/etiology , Adult
3.
BMC Infect Dis ; 20(1): 159, 2020 Feb 19.
Article in English | MEDLINE | ID: mdl-32075599

ABSTRACT

BACKGROUND: Varicella-zoster virus (VZV) infection can be diagnosed clinically once classical rash occurs but the diagnosis is challenging when typical rash is absent. We reported a case of fulminant central nervous system (CNS) VZV infection in a human immunodeficiency virus (HIV)-infected patient without typical VZV-related rash. CNS VZV infection was unexpected identified by metagenomic next-generation sequencing (mNGS). CASE PRESENTATION: A 28-year-old HIV-infected patient presented with neurological symptoms for 3 days. The patient, who was not suspected of VZV infection at admission, quickly progressed to deep coma during the first 24 h of hospitalization. An unbiased mNGS was performed on DNA extract from 300 µL cerebrospinal fluid (CSF) with the BGISEQ-50 platform. The sequencing detection identified 97,248 (out of 38,561,967) sequence reads uniquely aligned to the VZV genome, and these reads covered a high percentage (99.91%) of the VZV. Presence of VZV DNA in CSF was further verified by VZV-specific polymerase chain reaction and Sanger sequencing. Altogether, those results confirmed CNS VZV infection. CONCLUSIONS: This study suggests that mNGS may be a useful diagnostic tool for CNS VZV infection. As mNGS could identify all pathogens directly from CSF sample in a single run, it has the promise of strengthening our ability to diagnose CNS infections in HIV-infected patients.


Subject(s)
Central Nervous System Viral Diseases/diagnosis , HIV Infections/virology , Herpesvirus 3, Human/genetics , Varicella Zoster Virus Infection/diagnosis , Adult , Central Nervous System Viral Diseases/drug therapy , Central Nervous System Viral Diseases/etiology , Central Nervous System Viral Diseases/virology , Cerebrospinal Fluid/virology , DNA, Viral/cerebrospinal fluid , Herpesvirus 3, Human/pathogenicity , High-Throughput Nucleotide Sequencing , Humans , Male , Metagenome , Varicella Zoster Virus Infection/drug therapy , Varicella Zoster Virus Infection/etiology , Varicella Zoster Virus Infection/virology
4.
World J Pediatr Congenit Heart Surg ; 11(4): NP148-NP150, 2020 Jul.
Article in English | MEDLINE | ID: mdl-29793375

ABSTRACT

We describe the management and clinical course of two children with congenital bicuspid aortic valve. Neo-tricuspidization was performed in one case using CardioCel leaflets and two cusps were formed from CardioCel and grafted alongside one native leaflet in the other. Both patients developed bacterial endocarditis associated with varicella zoster virus infection and required a second surgical procedure.


Subject(s)
Aortic Valve Insufficiency/surgery , Aortic Valve/surgery , Cardiac Surgical Procedures/adverse effects , Endocarditis/etiology , Herpesvirus 3, Human , Postoperative Complications , Varicella Zoster Virus Infection/etiology , Aortic Valve/diagnostic imaging , Aortic Valve Insufficiency/diagnosis , Child , Echocardiography , Endocarditis/diagnosis , Endocarditis/virology , Female , Humans , Infant, Newborn , Varicella Zoster Virus Infection/diagnosis , Varicella Zoster Virus Infection/virology
5.
J Dig Dis ; 21(1): 46-51, 2020 Jan.
Article in English | MEDLINE | ID: mdl-31794121

ABSTRACT

OBJECTIVE: The prevalence of inflammatory bowel disease (IBD) has been increasing worldwide, and the risk of infection has increased due to the use of immunosuppressive and biologic medications. Some of these infections can be prevented with vaccinations. The aim of this study was to evaluate the vaccination practices of Chinese gastroenterologists for patients with IBD. METHODS: Questionnaires based on quick response codes were sent using email and the WeChat platform to gastroenterologists at 20 hospitals in China. The vaccination practices of the gastroenterologists, including vaccinating for hepatitis B, hepatitis A, and varicella, were assessed. RESULTS: Of the 468 gastroenterologists who received the questionnaire, 307 (65.6%) completed it. Of the gastroenterologists who were most concerned about hepatitis B; 83.4% always or frequently asked about an infection history, 53.7% took an immunization history, and 73.6% tested patients for hepatitis B infection. However, few gastroenterologists did so for hepatitis A or varicella. The proportion of patients who were asked about an infection and immunization history and tested for varicella infection was 16.0%, 15.0%, and 9.4%, respectively. Only a few gastroenterologists recommended vaccination for patients without an infection before IBD medical treatment (26.7% for hepatitis A, 45.6% for hepatitis B, and 28% for varicella vaccination). CONCLUSION: Vaccination practices for patients with IBD used by Chinese gastroenterologists vary greatly, suggesting that education about immunization is needed.


Subject(s)
Gastrointestinal Agents/adverse effects , Hepatitis, Viral, Human/prevention & control , Inflammatory Bowel Diseases/therapy , Vaccination , Varicella Zoster Virus Infection/prevention & control , Viral Vaccines/therapeutic use , Biological Products/adverse effects , Biological Products/therapeutic use , Chickenpox Vaccine/therapeutic use , China/epidemiology , Female , Gastroenterology/statistics & numerical data , Gastrointestinal Agents/therapeutic use , Health Care Surveys , Health Knowledge, Attitudes, Practice , Hepatitis A Vaccines/therapeutic use , Hepatitis B Vaccines/therapeutic use , Hepatitis, Viral, Human/etiology , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/epidemiology , Male , Professional Practice/statistics & numerical data , Vaccination/statistics & numerical data , Varicella Zoster Virus Infection/etiology , Viral Hepatitis Vaccines/therapeutic use
7.
Front Immunol ; 10: 1193, 2019.
Article in English | MEDLINE | ID: mdl-31191551

ABSTRACT

Autoimmune lymphoproliferative syndrome (ALPS) is caused by germline or somatic loss of function FAS mutations resulting in impaired apoptosis and consequent expansion of T-lymphocytes causing organomegaly and autoimmune anemia, neutropenia and thrombocytopenia. Herein, we report on a case of disseminated varicella zoster infection after post-partum vaccination in a patient found to have CD4 lymphopenia and eventually diagnosed with ALPS caused by a novel germline missense mutation in FAS death-domain. A subsequent retrospective analysis of 169 patients of the NIH ALPS-FAS cohort, revealed that CD4-T-cells lymphopenia (< 300 cells/µl) may occur in 5% of ALPS-FAS patients irrespectively of the underlying genetic defect, organomegaly or immunosuppressive treatment. Although immunophenotyping did not show depletion of specific CD4-T-cells subpopulations, CD4-lymphopenic ALPS-FAS subjects had an expansion of a subset of circulating T-follicular-helper (cTfh) cells, associated with autoantibody production (CCR7lowPD-1high). Furthermore, autoantibodies binding on CD4-T-cells were detected in 50% of the CD4-lymphopenic ALPS-FAS patients and caused cytotoxicity in a natural killer (NK)-mediated antibody-dependent-cellular cytotoxicity assay. Such autoantibodies can therefore be associated with CD4-T-cell death, impaired activation induced proliferation or impaired trafficking. The expansion of autoreactive T-cells in ALPS-FAS is known to be associated with autoimmune clinical manifestations, however our study reveals that ALPS-FAS can also be associated with a paradoxical depletion of CD4-T-cells due to the presence of autoantibodies on the surface of CD4-T-cells which can in turn result in increased susceptibility to opportunistic infections. These novel findings have implications for the diagnosis, clinical monitoring, and management of patients with ALPS-FAS.


Subject(s)
Autoantibodies/immunology , Autoimmune Lymphoproliferative Syndrome/complications , CD4-Positive T-Lymphocytes/immunology , Lymphopenia/etiology , Adolescent , Adult , Antibody Specificity , Antibody-Dependent Cell Cytotoxicity , Autoimmune Lymphoproliferative Syndrome/blood , Autoimmune Lymphoproliferative Syndrome/immunology , CD4 Lymphocyte Count , Case-Control Studies , Chickenpox Vaccine/adverse effects , Child , Disease Susceptibility , Female , Germ-Line Mutation , Humans , Immunocompromised Host , Lymphopenia/blood , Lymphopenia/immunology , Male , Pregnancy , Puerperal Disorders/etiology , Puerperal Disorders/immunology , Retrospective Studies , Vaccination , Varicella Zoster Virus Infection/etiology , Varicella Zoster Virus Infection/immunology , fas Receptor/deficiency , fas Receptor/genetics
8.
Clin Transplant ; 33(9): e13622, 2019 09.
Article in English | MEDLINE | ID: mdl-31162727

ABSTRACT

These updated guidelines from the American Society of Transplantation Infectious Diseases Community of Practice review the diagnosis, prevention, and management of varicella zoster virus (VZV) in the pre- and post-transplant period. Primary varicella is an uncommon complication post-solid-organ transplant (SOT), except among pediatric transplant patients and those seronegative for VZV. As the majority of SOT recipients are seropositive for VZV, herpes zoster (HZ) occurs frequently following SOT, particularly among recipients who are older (≥65 years of age) and those receiving more intensive immunosuppression. Transplant providers should aware of the increased risk for HZ-related complications such as dissemination, organ-specific involvement, and post-herpetic neuralgia. Treatment for localized zoster is primarily given as oral regimens, but those with more complicated presentations or those at risk for dissemination should be treated initially with IV therapy. Available antiviral prophylaxis regimens and vaccination strategies for varicella and HZ among these immunosuppressed patients remain a mainstay for prevention in the pre-and post-transplant periods. Finally, we discuss important approaches to addressing post-exposure prophylaxis and infection control practices for those SOT patients with documented VZV infections.


Subject(s)
Antiviral Agents/therapeutic use , Herpesvirus 3, Human/isolation & purification , Organ Transplantation/adverse effects , Practice Guidelines as Topic/standards , Varicella Zoster Virus Infection/diagnosis , Varicella Zoster Virus Infection/drug therapy , Humans , Societies, Medical , Transplant Recipients , Varicella Zoster Virus Infection/etiology
9.
BMC Infect Dis ; 19(1): 392, 2019 May 08.
Article in English | MEDLINE | ID: mdl-31068140

ABSTRACT

BACKGROUND: In Lao PDR, the epidemiology of varicella infection is uncertain, since it is not a notifiable disease and VZV outbreaks are rarely reported as fever/rash (F/R) diseases. METHODS: We estimated the seroprevalence of VZV (IgG ELISA) in different age cohorts (9 months to 46 years; N = 3139) and investigated VZV and 6 other viruses in patients during F/R outbreaks and in an ad hoc sentinel site in the context of the national reporting system (IgM ELISA, PCR). RESULTS: At least 80% of the sampled population had evidence of VZV infection before the age of 15. The largest increase in seroprevalence occurred between the age groups 1 to 5 and 6 to 7 year-olds. A VZV outbreak (clade 2) also occurred in this age group mostly during the first year of primary school (median age 6 years, interquartile range 4.0-7.5). During a dengue outbreak, 6% had varicella. At our F/R sentinel site, 14% of children with viral etiology were laboratory diagnosed as varicella and among others, a sizeable number of measles (N = 12) and rubella cases (N = 25) was detected compared to those reported for the whole country (N = 56 and 45), highlighting nationwide a large challenge of underreporting or misdiagnosis of these notifiable diseases because of lack of diagnostic laboratory capacity. CONCLUSION: We recommend strengthening the clinical and laboratory diagnosis of VZV, measles and rubella, the surveillance and reporting of notifiable F/R diseases by retraining of healthcare workers and by setting up sentinel sites and enhancing laboratory capacity.


Subject(s)
Exanthema/virology , Fever/virology , Varicella Zoster Virus Infection/epidemiology , Adolescent , Adult , Antibodies, Viral/blood , Chickenpox/diagnosis , Chickenpox/epidemiology , Child , Child, Preschool , Dengue/epidemiology , Dengue/etiology , Disease Outbreaks , Enzyme-Linked Immunosorbent Assay , Exanthema/epidemiology , Female , Fever/epidemiology , Herpes Zoster/epidemiology , Herpesvirus 3, Human/genetics , Herpesvirus 3, Human/immunology , Herpesvirus 3, Human/isolation & purification , Humans , Infant , Laos/epidemiology , Male , Measles/diagnosis , Measles/epidemiology , Middle Aged , Rubella/diagnosis , Rubella/epidemiology , Seroepidemiologic Studies , Varicella Zoster Virus Infection/etiology
11.
PLoS One ; 14(1): e0209365, 2019.
Article in English | MEDLINE | ID: mdl-30625182

ABSTRACT

BACKGROUND/PURPOSE: Limited evidence has been obtained on varicella-zoster virus (VZV) infection in patients with breast cancer as a complication related to adjuvant radiotherapy. We conducted a cohort study aimed to assess the risk of VZV infection in this patient setting. MATERIALS AND METHODS: We used the National Health Insurance Research Database to identify 65,981 patients with breast cancer in Taiwan who underwent breast surgery between 2000 and 2011. After a 1:1 propensity score match was obtained between patients with and without radiotherapy, a competing risk regression model was constructed to estimate the hazard ratios and the incidence rate difference (IRD) of VZV infection in the patients with breast cancer receiving radiotherapy and those not receiving radiotherapy. RESULTS: After adjusting for covariates, the radiotherapy cohort showed a 1.51-fold higher risk (95% confidence interval = 1.06-5.16, p = 0.02, IRD = 4.98/10000 person-years) of subsequent VZV infection than the nonradiotherapy cohort. Furthermore, VZV infection risk was 3.85-fold higher among patients aged >65 years who received radiotherapy than among those of the same age who did not receive radiotherapy (95% confidence interval = 1.1-13.4, p < 0.05, IRD = 11.09/10000 person-years). The risk increased with adjusted hazard ratio of 6.6 (95% confidence interval I = 1.51-28.8, p < 0.05, IRD = 32.01/10,000 person-years) and 7.08 (95% confidence interval = 1.64-30.5, p < 0.01, IRD = 35.72/10,000 person-years) in follow-up period less than 3 months and 3-5 months respectively. CONCLUSION: Radiotherapy was associated with an increased risk of VZV infection among patients with breast cancer. The risk was significantly higher in older patient (>65 years old) and/or those who received chemotherapy. Regular clinical follow-up and additional serological testing in the first 5 months after radiotherapy are recommended.


Subject(s)
Breast Neoplasms/complications , Breast Neoplasms/radiotherapy , Radiotherapy, Adjuvant/adverse effects , Varicella Zoster Virus Infection/etiology , Adult , Aged , Cohort Studies , Databases, Factual , Female , Humans , Incidence , Middle Aged , Propensity Score , Proportional Hazards Models , Registries , Risk Factors , Taiwan/epidemiology , Varicella Zoster Virus Infection/epidemiology
13.
Int Ophthalmol ; 38(3): 1329-1332, 2018 Jun.
Article in English | MEDLINE | ID: mdl-28536762

ABSTRACT

PURPOSE: To report a case of bilateral varicella zoster virus (VZV)-associated acute retinal necrosis (ARN) occurring after both eyes sequential cataract surgery in an elderly immunocompromised patient. METHODS: Medical records and investigation results of the patient were reviewed. RESULTS: Patient experienced floaters and blurring of vision in both eyes 4 weeks after her second uncomplicated cataract surgery. Clinical signs of granulomatous keratic precipitates, prominent vitritis, retinitis and vascular thrombosis were noted in both eyes. Aqueous samples from both eyes were positive for VZV. Disease was treated with intravitreal foscarnet bilaterally and 10 days of systemic intravenous acyclovir (10 mg/kg) followed by oral valaciclovir 1 g three times daily. Final visual acuity at 4 months after initial presentation was 20/60 in both eyes with no retinal detachment noted. CONCLUSIONS: Cataract surgery may have been the trigger for bilateral VZV-associated ARN. Immunocompromised patients can develop ARN and require close observation after cataract surgery. This is, to our knowledge, the first report of bilateral ARN following routine cataract surgery.


Subject(s)
Cataract Extraction/adverse effects , Eye Infections, Viral/etiology , Herpesvirus 3, Human/immunology , Immunocompromised Host , Retinal Necrosis Syndrome, Acute/etiology , Surgical Wound Infection/etiology , Varicella Zoster Virus Infection/etiology , Aged , Antibodies, Viral/immunology , Eye Infections, Viral/virology , Female , Humans , Retinal Necrosis Syndrome, Acute/immunology , Retinal Necrosis Syndrome, Acute/virology , Surgical Wound Infection/immunology , Surgical Wound Infection/virology , Varicella Zoster Virus Infection/diagnosis , Varicella Zoster Virus Infection/virology , Visual Acuity
14.
Commun Dis Intell Q Rep ; 41(3): E264-E278, 2017 Sep 01.
Article in English | MEDLINE | ID: mdl-29720076

ABSTRACT

INTRODUCTION: The Paediatric Active Enhanced Disease Surveillance (PAEDS) network is a hospital-based active surveillance system employing prospective case ascertainment for selected serious childhood conditions, particularly vaccine preventable diseases and potential adverse events following immunisation (AEFI). PAEDS data is used to better understand these conditions, inform policy and practice under the National Immunisation Program, and enable rapid public health responses for certain conditions of public health importance. PAEDS enhances data available from other Australian surveillance systems by providing prospective, detailed clinical and laboratory information on children with selected conditions. This is the second of the planned annual PAEDS reporting series, and presents surveillance data for 2015. METHODS: Specialist surveillance nurses screened hospital admissions, emergency department records, laboratory and other data, on a daily basis in 5 paediatric tertiary referral hospitals in New South Wales, Victoria, South Australia, Western Australia and Queensland to identify children with the selected conditions. Standardised protocols and case definitions were used across all sites. Conditions under surveillance in 2015 included acute flaccid paralysis (a syndrome associated with poliovirus infection), acute childhood encephalitis (ACE), influenza, intussusception (IS; a potential AEFI with rotavirus vaccines), pertussis and varicella-zoster virus infection (varicella and herpes zoster). Most protocols restrict eligibility to hospitalisations, ED only presentations are also included for some conditions. METHODS: : In 2015, there were 674 cases identified across all conditions under surveillance. Key outcomes of PAEDS included: contribution to national AFP surveillance to reach WHO reporting targets; identification of signals for Mycoplasma pneumoniae and parechovirus-related outbreaks (ACE surveillance); and demonstration of high influenza activity with vaccine effectiveness (VE) analysis supportive of vaccination. Surveillance for IS remains ongoing with any identified AEFIs reported to the relevant State Health Department; varicella and herpes zoster case numbers decreased slightly from previous years in older children not eligible for catch-up. Pertussis case numbers increased in early 2015 and analysis of cases in children aged <1 year demonstrated the importance of timely childhood and maternal immunisation. CONCLUSIONS: PAEDS continues to provide unique policy-relevant data on serious paediatric conditions using hospital-based sentinel surveillance.


Subject(s)
Acute Febrile Encephalopathy/epidemiology , Bacterial Vaccines/adverse effects , Influenza, Human/epidemiology , Intussusception/epidemiology , Paraplegia/epidemiology , Varicella Zoster Virus Infection/epidemiology , Viral Vaccines/adverse effects , Whooping Cough/epidemiology , Acute Disease , Acute Febrile Encephalopathy/etiology , Adolescent , Australia/epidemiology , Child , Child, Preschool , Disease Notification/statistics & numerical data , Female , Hospitals , Humans , Infant , Influenza, Human/etiology , Intussusception/etiology , Male , Paraplegia/etiology , Public Health Surveillance , Vaccination/adverse effects , Varicella Zoster Virus Infection/etiology , Whooping Cough/etiology
SELECTION OF CITATIONS
SEARCH DETAIL
...